Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2025; 17(2): 102734
Published online Feb 27, 2025. doi: 10.4254/wjh.v17.i2.102734
Association between Helicobacter pylori infection and metabolic dysfunction-associated steatohepatitis: From an analysis of a population-based study
Cheng-Fei Zhao
Cheng-Fei Zhao, School of Pharmacy and Medical Technology, Putian University, Putian 351100, Fujian Province, China
Cheng-Fei Zhao, Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine in University of Fujian Province, Putian University, Putian 351100, Fujian Province, China
Author contributions: Zhao CF designed, wrote, and revised this paper.
Supported by Scientific Research Project of Putian University, No. 2022059.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cheng-Fei Zhao, MD, PhD, Associate Professor, School of Pharmacy and Medical Technology, Putian University, No. 1133 Xueyuan Road, Chengxiang District, Putian 351100, Fujian Province, China. zhaochengfei209@163.com
Received: October 28, 2024
Revised: November 25, 2024
Accepted: December 23, 2024
Published online: February 27, 2025
Processing time: 115 Days and 19.8 Hours
Core Tip

Core Tip: The association between Helicobacter pylori (H. pylori) infection and metabolic dysfunction-associated steatohepatitis (MASH) highlights a potentially significant but complex relationship. This article critically reviews recent findings and proposes innovative research directions, including genetic and microbiome studies, longitudinal evaluations of H. pylori eradication effects on MASH, and mechanistic investigations into inflammation and metabolic pathways. Personalized medicine approaches are also suggested to optimize MASH management based on individual risk factors. These strategies aim to uncover the underlying mechanisms linking H. pylori to liver disease, offering new opportunities for targeted diagnostic and therapeutic interventions in metabolic liver disorders.